Journal Articles

Donald and Barbara Zucker School of Medicine
Academic Works

2015

Clinical features, and gene- and microRNAexpression patterns in adult acute leukemia patients
with t(11;19)(q23;p13.1) and
t(11;19)(q23;p13.3)
B. Bhatnagar
J. S. Blachly
J. Kohlschmidt
A. K. Eisfeld
S. Volinia
See next page for additional authors

Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
Part of the Oncology Commons
Recommended Citation
Bhatnagar B, Blachly J, Kohlschmidt J, Eisfeld A, Volinia S, Nicolet D, Carroll A, Block A, Kolitz JE, Bloomfield C, . Clinical features,
and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3). .
2015 Jan 01; 30(7):Article 2210 [ p.]. Available from: https://academicworks.medicine.hofstra.edu/articles/2210. Free full text
article.

This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for
inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works. For more
information, please contact academicworks@hofstra.edu.

Authors

B. Bhatnagar, J. S. Blachly, J. Kohlschmidt, A. K. Eisfeld, S. Volinia, D. Nicolet, A. J. Carroll, A. M. Block, J. E.
Kolitz, C. D. Bloomfield, and +3 additional authors

This article is available at Donald and Barbara Zucker School of Medicine Academic Works:
https://academicworks.medicine.hofstra.edu/articles/2210

HHS Public Access
Author manuscript
Author Manuscript

Leukemia. Author manuscript; available in PMC 2017 January 01.
Published in final edited form as:
Leukemia. 2016 July ; 30(7): 1586–1589. doi:10.1038/leu.2015.345.

Clinical features and gene- and microRNA-expression patterns
in adult acute leukemia patients with t(11;19)(q23;p13.1) and
t(11;19)(q23;p13.3)
B Bhatnagar1,2,9, JS Blachly1,2,9, J Kohlschmidt2,3, A-K Eisfeld2, S Volinia4, D Nicolet2,3, AJ
Carroll5, AW Block6, JE Kolitz7, RM Stone8, K Mrózek2, JC Byrd1,2, and CD Bloomfield1,2

Author Manuscript

B Bhatnagar: bhavana.bhatnagar@osumc.edu; CD Bloomfield: clara.bloomfield@osumc.edu
1Division
2The

of Hematology, Department of Internal Medicine, Columbus, OH, USA

Ohio State University Comprehensive Cancer Center, Columbus, OH, USA

3Alliance

for Clinical Trials in Oncology Statistics and Data Center, Mayo Clinic, Rochester, MN,

USA
4Department

of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara,

Italy
5University
6Roswell

of Alabama at Birmingham, Birmingham, AL, USA

Park Cancer Institute, Buffalo, NY, USA

7Monter

Author Manuscript

Cancer Center, Hofstra North Shore-Long Island Jewish, School of Medicine, Lake
Success, NY, USA

8Dana-Farber

Cancer Institute, Boston, MA, USA

Author Manuscript

Translocations involving the KMT2A (MLL) gene, located at 11q23, and two different
partner genes, ELL and MLLT1, located at 19p13.1 and 19p13.3, respectively, have been
reported in both acute myeloid leukemia (AML) and acute lymphoblastic leukemia
(ALL).1,2 However, there are limited data describing clinical and molecular differences
between adult patients with t(11;19)(q23;p13.1) and those with t(11;19)(q23;p13.3). Neither
the Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer3 nor large
studies correlating chromosome abnormalities with clinical outcome4 distinguish the two
types of t(11;19); instead they combine both into one cytogenetic group. Herein, we report
the largest, to our knowledge, series of 35 adults with acute leukemia and t(11;19)
(q23;p13.1) or t(11;19)(q23;p13.3) who were treated on Cancer and Leukemia Group B
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(CALGB)/Alliance for Clinical Trials in Oncology (Alliance) trials. Our study is also the
largest to describe the clinical features and disease outcomes of these patients as well as to
provide mutational analyses, and gene- and microRNA (miR)-expression patterns, thereby
providing the rationale to identify each as separate entities.
We identified and clinically characterized 19 adults with t(11;19) (q23;p13.1) and AML and
16 with t(11;19)(q23;p13.3), 12 with AML, three with ALL and one with ambiguous lineage
acute leukemia (ALAL), who received AML-directed therapy and is grouped with AML
patients, enrolled onto a prospective cytogenetics companion trial, CALGB 8461. We also
performed RNA, microRNA and targeted DNA-sequencing studies on subsets of patients in
each cytogenetic group. See Supplementary Information for methods details.
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Translocation (11;19)(q23;p13.1) was found exclusively in AML patients; however, t(11;19)
(q23;p13.3) was detected in both AML and ALL patients. The only significant clinical
differences between AML patients with either translocation were the higher marrow (P =
0.003) and blood (P = 0.004) blast percentages in patients with t(11;19)(q23;p13.3) (Table
1). Among AML patients, there were no major differences between the two cytogenetic
groups with respect to complete remission (CR) rates, disease-free survival or overall
survival. Both translocations were associated with a poor prognosis, with a median overall
survival of 8.2 months for t(11;19) (q23;p13.1) patients and 10.0 months for t(11;19)
(q23;p13.3) AML patients (Table 1, Supplementary Figure S1). The median follow-up for
the four patients alive and without an event is 6.9 years.
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Four (21%) t(11;19)(q23;p13.1) patients underwent either autologous (patients no. 3, 16) or
allogeneic (no. 5, 6) hematopoietic stem-cell transplantation (HSCT) in CR1. Two (15%)
AML patients with t(11;19)(q23;p13.3) received autologous (no. 30) or allogeneic (no. 25)
HSCT in CR1. Three of these six patients remain alive and disease-free at last follow-ups of
38.4 months (no. 6), 90.7 months (no. 25) and 134.3 months (no. 30) after diagnosis.
Clinical and cytogenetic data for individual patients are provided in Supplementary Tables
S1–S3.
We compared our findings with the literature and found them mostly concordant
(Supplementary Tables S4 and S5). Others have also found t(11;19)(q23;p13.1) exclusively
in AML patients, who were primarily female and had M4/M5 marrow morphology.
However, t(11;19)(q23;p13.3) patients in the literature were mainly male, whereas twothirds of CALGB/Alliance patients with t(11;19) (q23;p13.3) were female.
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Cytogenetically, t(11;19)(q23;p13.3) AML patients tended to have a higher incidence of
secondary chromosome abnormalities at diagnosis than AML patients with t(11;19)
(q23;p13.1) (62% vs 26%, P=0.07). In most t(11;19)(q23;p13.1) patients (74%), the
translocation was detected as an isolated chromosome abnormality; however, five patients
had additional clonal abnormalities including trisomy 8 (+8), trisomy 21, paracentric
inversion within 12p, deletion of 20q and a complex karyotype. The most common
secondary abnormality was +8, found in six AML patients, but its incidence was higher
among patients with t(11;19)(q23;p13.3) than those with t(11;19)(q23;p13.1) (83% vs 17%)
(Supplementary Tables S1 and S2). In six of the seven patients for whom cytogenetic data
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were available at the time of relapse, the translocation present at diagnosis was also found at
relapse.
When we combined our data with the literature, secondary abnormalities occurred
significantly more often in t(11;19) (q23;p13.3) patients (55% vs 21%, P < 0.001). Our data
and the literature identified unbalanced structural abnormalities of 12p as novel recurrent
secondary rearrangements. These 12p rearrangements, invariably leading to loss of 12p
genetic material, were present at diagnosis in four patients (no. 29 and 30, cases reported by
Ninomiya et al.5 and Cerveira et al.6), all with t(11;19)(q23; p13.3). A fifth patient with
t(11;19)(q23;p13.3)7 and one patient with t(11;19)(q23;p13.1) (no. 17) acquired similar
unbalanced 12p abnormalities at relapse. Notably, among adult patients, unbalanced 12p
abnormalities were detected exclusively in patients diagnosed with AML.3
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We next performed targeted DNA-sequencing studies in 13 AML patients with t(11;19)
(q23;p13.1) and eight patients with t(11;19)(q23;p13.3) (seven with AML and one with
ALAL) to search for molecular differences between the two cytogenetic groups of AML
patients (Figure 1a and Supplementary Table S6). In general, the mutation rate was low in
both patient subsets using a variant allele frequency cutoff of 0.3 (Figure 1a). Whereas
FLT3-TKD and mutations in KRAS, NRAS, CEBPA (single mutation) and TET2 were the
only mutations observed in the t(11;19)(q23;p13.1) group, patients with t(11;19)(q23;p13.3)
had a wider mutational spectrum. Specifically, t(11;19)(q23;p13.3) patients harbored
mutations in ASXL1, ETV6, GATA2, KIT and TET2. Notably, we found no recurrent AMLassociated mutations such as double CEBPA mutations or mutations in DNMT3A, FLT3ITD, IDH1, IDH2, NPM1, TP53 or WT1 in either group. The relatively low number of gene
mutations found in CALGB/Alliance patients is consistent with the findings reported by The
Cancer Genome Atlas Research Network,8 in which patients with KMT2A fusions had the
fewest number of recurrent mutations (with a mean of approximately two mutations in the
coding regions of the genome (tier 1 mutations)) among 10 AML categories analyzed in that
study. Our findings thus support the suggestion that gene fusions involving KMT2A, such as
KMT2A-MLLT1 and KMT2A-ELL, require a smaller number of cooperating mutations
than other AML-initiating genetic alterations.8
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Stranded mRNA sequencing was performed on six AML patient samples with t(11;19)
(q23;p13.1) (no. 5, 6, 14, 15, 16, 18) and seven with t(11;19)(q23;p13.3) (six with AML (no.
21, 24, 27, 28, 30, 31) and one with ALAL (no. 20)). Gene-expression profiles of t(11;19)
(q23;p13.1) patients clustered tightly, whereas expression profiles of t(11;19)(q23;p13.3)
patients were more diffuse and may represent two distinct subgroups (Figure 1b,
Supplementary Figure S3). Of note, the outlier case (no. 20) was reconfirmed by
cytogenetics and RNA-sequencing to harbor t(11;19)(q23;p13.3) (Supplementary Table S8).
Because the expression profiles of the t(11;19)(q23;p13.1) cases were very similar, a large
number of protein-coding genes were found to be differentially expressed between
cytogenetic groups at the 1% false discovery rate (q-value) level. To further enhance this, we
eliminated the two cases clustering apart from their cytogenetic group (no. 16 and 20). Using
a q-value cutoff of 0.01, a total of 690 genes were differentially expressed between the
cytogenetic groups (Supplementary Table S9). We examined these 690 distinguishing genes
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with Gene Set Enrichment Analysis9,10 to probe for biological differences between the two
groups and observed that patients with t(11;19)(q23;p13.3) had a molecular profile with a
more immature myeloid gene-expression pattern than patients with t(11;19)(q23;p13.1)11
(Supplementary Figure S2).
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In the context of disease response, 54 genes were differentially expressed between patients
who achieved CR and those who did not, with 37 genes up- and 17 genes downregulated in
patients who did not attain CR (Supplementary Table S10A). A repetition of this analysis
after controlling for the translocation partner yielded a longer list of 72 genes
(Supplementary Table S10B). Genes associated with failure to achieve CR were enriched for
genes encoding zinc-finger transcription factors, many of which reside on the 19q arm. The
biology of these, and other genes associated with CR attainment, should be explored in
future studies. Consistent with prior reports,12,13 MECOM (EVI1) expression was observed
in both our KMT2A-ELL and KTM2A-MLLT1 AML cases. None of five patients with
MECOM overexpression achieved a CR, whereas six of eight patients with low MECOM
expression did.
We also performed small RNA sequencing on six AML patient samples with t(11;19)
(q23;p13.1) and eight with t(11;19)(q23; p13.3) (seven with AML and one with ALAL).
Again, these groups displayed distinct expression profiles; miR-expression profiling
revealed 31 specific miRs that were differentially expressed between the cytogenetic groups.
As with gene-expression, the miR-expression profiles clustered well overall (Figure 1c).
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Lavallée et al.14 recently explored the transcriptomes of four patients with KMT2A-MLLT1
(MLL-ENL) and three with KMT2A-ELL (MLL-ELL), and reported differing geneexpression patterns between patients with and without KMT2A gene rearrangements. With
our larger number of t(11;19) cases we were able to directly compare the transcriptional
profiles of AML with KMT2A-MLLT1 and KMT2A-ELL fusions. Our results and those of
Lavallée et al.14 support further exploration of biological differences between patients with
KMT2A-MLLT1 and those with KMT2A-ELL.
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In conclusion, our results add to the limited literature pertaining to t(11;19) in adults with
acute leukemia and demonstrate that t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3) are indeed
two distinct rearrangements associated with unique clinical and cytogenetic features. Both
translocations, similar to the majority of other 11q23/KMT2A rearrangements, carry a poor
prognosis, and both our study and published reports15 suggest that these patients should
receive allogeneic HSCT in first remission. RNA-sequencing studies showed distinct geneand miR-expression patterns between AML patients with t(11;19)(q23;p13.1) and those with
t(11;19)(q23;p13.3) supporting the recognition of these two translocations as separate
entities.
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Figure 1.

(a) Oncoprint of pre-treatment gene mutations detected in t(11;19)(q23;p13.1) AML patients
and t(11;19)(q23;p13.3) AML patients plus one with ambiguous lineage acute leukemia
(ALAL) using a variant allele frequency cutoff of 0.3. Not marked is a single CEBPA
mutation found in patient no. 13. (b) Principle component analysis plot depicting relative
gene-expression profiles of six AML patients with t(11;19)(q23; p13.1), and six patients
with AML plus one with ALAL (no. 20) harboring t(11;19)(q23;p13.3). Each dot represents
one patient and is color-coded by translocation partner. X and Y axes: Euclidean distance
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between gene-expression profiles in arbitrary units. (c) Heat map of the microRNAexpression patterns of t(11;19)(q23;p13.1) AML patients versus those of AML patients, plus
one with ALAL, with t(11;19)(q23;p13.3). The heat map shows expression levels of 31
miRNAs found differentially expressed between t(11;19)(q23;p13.1) versus t(11;19)
(q23;p13.3) cases. Rows represent probe sets and columns individual patients. Patients are
grouped according to t(11;19)(q23;p13.1) versus t(11;19)(q23; p13.3), and genes are ordered
by hierarchical cluster analysis. Expression values of the probe sets are represented by color:
blue represents expression less than the median value for the given probe set, and yellow,
expression greater than the median value for the given probe set.
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Comparison of clinical characteristics of patients with t(11;19) (q23;p13.1) and those with t(11;19)(q23;p13.3)
Characteristic

t(11;19)
(q23;p13.1)
AML
(n = 19)

t(11;19)
(q23;p13.3)
AML
(n = 13)a

Age, y

P-valueb

t(11;19)
(q23;p13.3)
ALL
(n=3)

0.42

Median

54

38

79

Range

20–70

25–84

30–79

13 (68)

9 (69)

Age group, n (%)
<60 y
≥60 y

1.00

6 (32)

4 (31)

11 (58)

9 (69)

White

15 (83)

11 (85)

Non-white

3 (17)

2 (15)

Female sex, n (%)
Race, n (%)

1 (33)
2 (67)
0.71

3 (100)

1.00

Author Manuscript

Hemoglobin, g/dl

2 (67)
1 (33)
0.51

Median

9.1

9.5

12.5

Range

2.8–15.8

6.2–12.0

7.7–13.8

Platelet count, × 109/l

1.00

Median

49

56

66

Range

16–163

20–184

11–165

Median

29.4

10.0

Range

2.1–97.5

2.3–80.7

WBC, × 109/l

0.14

Bone marrow blasts, %

92.5
11.8–231.9
0.003
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Median

57

87

90

Range

26–93

45–96

65–94

Median

10

58

Range

0–75

2–86

Blood blasts, %

0.004

Therapy-related
leukemia, n (%)

46
10–98
0.20

Yes

0 (0)

2 (15)

0 (0)

No

19 (100)

11 (85)

3 (100)

FAB (centrally reviewed),
n (%)
M0

—

Author Manuscript

0 (0)

1 (9)

M1

1 (6)

1 (9)

M2

3 (17)

0 (0)

M4

7 (39)

0 (0)

M5

7 (39)

6 (55)

M6

0 (0)

0 (0)

Other

0 (0)

3 (27)

NR

Leukemia. Author manuscript; available in PMC 2017 January 01.

Bhatnagar et al.

Characteristic

Author Manuscript

Extramedullary
involvement, n (%)
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t(11;19)
(q23;p13.1)
AML
(n = 19)

t(11;19)
(q23;p13.3)
AML
(n = 13)a

P-valueb

t(11;19)
(q23;p13.3)
ALL
(n=3)

5 (29)

3 (27)

1.00

0 (0)

Transplantation in CR1, n
(%)
Allo

1.00
2 (11)

1 (8)

1 (33)

Auto

2 (11)

1 (8)

0 (0)

None

15 (78)

11 (85)

2 (67)

Translocation (11;19), n
(%)

0.07
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Occurring as a sole
abnormality

14 (74)

5 (38)

2 (67)

With additional
abnormalities

5 (26)

8 (62)

1 (33)

9 (47)

8 (62)

5.6

9.7

% Disease-free at
12 months, (95% CI)

33 (8–62)

25 (4–56)

% Disease-free at
60 months, (95% CI)

22 (3–51)

25 (4–56)

Complete remission, n
(%)

Disease-free survival
Median, months

Overall survival
Median, months

8.2

10.0

% Alive at 12 months,
% (95% CI)

21 (7–41)

46 (19–70)

% Alive at 60 months,
% (95% CI)

11 (2–28)

15 (2–39)

0.49

2 (67)

0.78

2.1 and 7.9 mo

0.59

0.8, 5.2 and
8.8 mo
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Abbreviations: allo, allogeneic hematopoietic stem-cell transplantation; auto, autologous hematopoietic stem-cell transplantation; CI, confidence
interval; CR1, first complete remission, FAB, French-American-British classification; mo, months; n, number; NR, not reported; WBC, white blood
count; y, years.

a

Includes one patient with ambiguous lineage acute leukemia.

b

P-values for categorical variables are from Fisher’s exact test, P-values for continuous variables are from Wilcoxon rank sum test for comparisons
between AML patients with t(11;19)(q23;p13.1) and those with t(11;19)(q23;p13.3).
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